title: Fertility-sparing treatment of endometrial cancer precursors among young women: a reproductive point of view.
abstract: BACKGROUND
  Early-stage endometrial cancer and complex atypical hyperplasia are treated with hysterectomy and bilateral salpingo-oophorectomy. An emerging issue among younger women affected is the possibility of a fertility-sparing treatment with progestative therapy and close follow-up.
  
  
  OBJECTIVE
  To assess the possibility of conceiving after a diagnosis of atypical endometrial hyperplasia among women younger than 40 years old, in term of delaying definitive treatment and achieving pregnancy.
  
  
  METHODS
  15 women younger than 40 years old with complex CAH or early carcinoma of the endometrium and a wish to preserve fertility. Progestins were administered orally for at least a 12 weeks period. Endometrial biopsies were used at follow-up.
  
  
  RESULTS
  In 11 women, a complete pathological remission of the disease was observed. 4 pregnancies were attained in 4 women. 3 showed progression and underwent definitive surgery at 18 months. 1 showed no response at 24 months and 3 cycles and was counseled to receive a hysterectomy.
  
  
  CONCLUSIONS
  A conservative approach in patients younger than 40 years appears a valid option, and a progestative therapy trial should be attempted whether a valid consensus is attained. Considering the risk to find AEH at biopsies and eventually a carcinoma at hysterectomy (25% of cases) a careful management is strictly required.
authors.affiliation: Department of Obstetrics, Sapienza University of Rome, Rome, Italy. enzo.ricciardi@uniroma1.it
authors.forename: E
authors.initials: E
authors.lastname: Ricciardi
authors.forename: P
authors.initials: P
authors.lastname: Maniglio
authors.forename: A
authors.initials: A
authors.lastname: Frega
authors.forename: R
authors.initials: R
authors.lastname: Marci
authors.forename: D
authors.initials: D
authors.lastname: Caserta
authors.forename: M
authors.initials: M
authors.lastname: Moscarini
mesh_terms: D000284:Administration, Oral; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D001706:Biopsy; D018450:Disease Progression; D004334:Drug Administration Schedule; D004714:Endometrial Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016889:Endometrial Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D005260:Female; D005298:Fertility; D059247:Fertility Preservation; D013509:Gynecologic Surgical Procedures; D006801:Humans; D015907:Hysteroscopy; D007247:Infertility, Female / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D009367:Neoplasm Staging; D011230:Precancerous Conditions / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011247:Pregnancy; D018873:Pregnancy Rate; D011372:Progestins / Q000008:administration & dosage*; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D011372:Progestins